Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

@article{Verschraegen1997PhaseIS,
  title={Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.},
  author={Claire F. Verschraegen and Tally Levy and Andrzej P. Kudelka and E Llerena and Kevin Ende and R. S. Freedman and Creighton L. Edwards and M H Hord and Melissa D Steger and Andrew L Kaplan and Dirk G{\"u}nter Kieback and Ami Fishman and John J. Kavanagh},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1997},
  volume={15 2},
  pages={625-31}
}
PURPOSE A phase II study was performed to evaluate the antitumor activity and toxicity of irinotecan (CPT-11), a water-soluble derivative of camptothecin, in patients with prior chemotherapy-treated squamous cell cancer of the cervix. PATIENTS AND METHODS Forty-two patients were included in the study. The median age was 44 years (range, 24 to 59 years). The median Zubrod performance status was 1. All patients were refractory to first-line chemotherapy and 88% had received prior radiotherapy… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…